We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

PERKIN ELMER CORPORATION

PerkinElmer provides detection technologies to detect and identify diseases, imaging technologies to help visualize s... read more Featured Products: More products

Download Mobile App





PerkinElmer Demonstrates High-Throughput MSMS Dried Blood Spot Screening Solutions at Medlab Middle East 2021

By LabMedica International staff writers
Posted on 21 Jun 2021
Print article
Image: PerkinElmer QSight 225 LC/MS/MS (Photo courtesy of PerkinElmer, Inc.)
Image: PerkinElmer QSight 225 LC/MS/MS (Photo courtesy of PerkinElmer, Inc.)
PerkinElmer, Inc. (Waltham, MA; USA) demonstrated its high-throughput MSMS dried blood spot screening solutions at the 2021 edition of Medlab Middle East, the leading medical laboratory exhibition in the region for over 20 years.

On display at the event was the PerkinElmer QSight 225 LC/MS/MS system developed uniquely for newborn screening with the option for tier 2 testing – using just a single heel-prick dried blood spot (DBS) card. The QSight system delivers a unique combination of self-cleaning MS/MS instrumentation that provides exceptional system uptime, a simple setup process, and easy-to-use database software that simplifies review and analysis - plus kits and reagents, training, and support. The QSight system includes a high capacity autosampler, precision binary pump, best in class MS detector, and easy to use instrument control and data analysis software that have been optimized to run hundreds of samples per day, for weeks at a time, to generate consistent results with minimum maintenance or downtime.

PerkinElmer also exhibited the Opera Phenix High Content Screening System, the premier confocal solution for today's most demanding high content applications. Drawing on over a decade of experience with the industry-leading Opera High Content Screening System, the Opera Phenix is designed for high-throughput, phenotypic screening and assays involving complex disease models, such as live cells, primary cells and microtissues. In addition, PerkinElmer highlighted the VICTOR Nivo multimode reader that breaks new ground, packing all popular detection modes into the industry’s smallest benchtop footprint. The successor to the highly popular VICTOR X system - the world’s first multimode plate reader - the VICTOR Nivo system detects absorbance, luminescence, fluorescence intensity, time-resolved fluorescence, fluorescence polarization and now Alpha technologies, making it perfect for everyday biochemical and cell-based assays, including kinetic measurements.

At this year’s Medlab Middle East, PerkinElmer displayed the LC 300 chromatography platform that redefines and simplifies LC, delivering the flexibility, performance, and efficiency to tackle challenging analytical demands. Users can choose between a 10k-psi system for HPLC and an 18k-psi system for ultraprecise UHPLC analysis. Both offer patented valve technology and sample handling options to accommodate multiple sample tray formats. And SimplicityChrom 21CFR11 software delivers intuitive instrument control, while an integrated color display shows immediate system status. Combined with CDS third-party drivers for commercial systems, this offers a powerful and simple LC solution. Also on display was the chemagic 360 instrument, with dimensions of only 80 x 80 cm and its unique sample volume flexibility, making it the ideal solution for nucleic acid isolation in human genetics, biobanking, HLA typing, viral and bacterial detection.

Related Links:
PerkinElmer, Inc.

Automated ELISA-IFA-BLOT Processor AP 22
Gold Supplier
Quality Control Material
Multichem U
New
Reusable Readers
Lumos Reusable Readers
New
Laboratory Centrifuge
M-BASIC

Print article

Channels

Industry

view channel
Image: Fujirebio has acquired ADx NeuroSciences for 40 million Euros (Photo courtesy of Pexels)

Fujirebio's Belgian Acquisition Targets Neurodegenerative Diagnostics

Fujirebio Holdings, Inc. (Tokyo, Japan) has announced the acquisition of ADx NeuroSciences (Gent, Belgium) for EUR 40 million in a deal that is expected to close in July 2022, pending the satisfaction... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.